Drug Profile
Research programme: anti-HER2 monoclonal antibodies - Genmab
Alternative Names: HuMax-Her2Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Genmab
- Class
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)